Sickle Cell Disease patients and the use of disease-modifying treatments

A week af­ter one obe­si­ty biotech, Car­mot Ther­a­peu­tics, backed out of its IPO plans in fa­vor of a $2.7 bil­lion sale to Roche, an­oth­er an­nounced

Te­va inks deal with Roy­al­ty Phar­ma for schiz­o­phre­nia drug: The Is­raeli drug­mak­er said Mon­day that it will re­ceive $100 mil­lion to com­plete an on­go­ing Phase